Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection
- PMID: 18261569
- DOI: 10.1016/j.transproceed.2007.12.016
Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection
Abstract
Introduction: During kidney transplantation, the first contact between the recipient's immune system and the donor organ takes place immediately following the arterial anastomosis. The aim of this study was to evaluate the efficacy of a single, low-dose anti-thymocyte globulin (ATG) prophylaxis in the reduction of early acute rejection in renal allograft recipients.
Methods: In a randomized, controlled clinical trial, we studied the rate of acute rejection within the first month of kidney transplantation in patients who had received their transplant at a single center between the years 2004 and 2007. The patients were divided into 2 groups: group 1 (n = 37) received cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone; group 2 (n = 31) received the above-mentioned agents plus a single ATG bolus (Thymoglobulin; SangStat, Lyon, France; 4-5 mg/kg) the night before the transplantation ( approximately 12 hours before the operation). Blood urea and serum creatinine levels were measured regularly in the posttransplantation period. Acute allograft rejection was justified clinically and/or pathologically. Statistical analysis was performed by SPSS 13.0 using Student t test and Fisher exact test. A P value < or = .05 was considered to indicate statistical significance.
Results: There were no significant differences regarding the age and gender ratio between the 2 groups. Acute allograft rejection was found in 32.4% (n = 12) of group 1 patients, and was reduced to 12.9% (n = 4) in group 2 (P = .05). Hence, the first-month acute rejection episodes decreased by approximately 60% with ATG prophylaxis in renal transplant recipients.
Conclusion: Prophylactic administration of a single and low-dose ATG the night before kidney transplantation could reduce the risk of acute allograft rejection in renal transplant recipients. However, further studies with a greater number of patients should be conducted to confirm these results.
Similar articles
-
One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.Transplant Proc. 2007 Jan-Feb;39(1):69-72. doi: 10.1016/j.transproceed.2006.10.007. Transplant Proc. 2007. PMID: 17275476
-
Safety of low-dose cyclosporine therapy before transplantation in kidney allograft recipients.Transplant Proc. 2009 Sep;41(7):2757-60. doi: 10.1016/j.transproceed.2009.06.149. Transplant Proc. 2009. PMID: 19765427
-
Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.Clin Nephrol. 1996 Jan;45(1):22-8. Clin Nephrol. 1996. PMID: 8616953
-
Tolerance induction in clinical transplantation.Transpl Immunol. 2004 Sep-Oct;13(2):117-30. doi: 10.1016/j.trim.2004.05.009. Transpl Immunol. 2004. PMID: 15380542 Review.
-
Clinical aspects of allograft rejection.Transplant Proc. 1974 Dec;6(4 Suppl 1):71-7. Transplant Proc. 1974. PMID: 4612907 Review. No abstract available.
Cited by
-
Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.Am J Transplant. 2019 Aug;19(8):2252-2261. doi: 10.1111/ajt.15342. Epub 2019 Apr 3. Am J Transplant. 2019. PMID: 30838775 Free PMC article.
-
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2. Cochrane Database Syst Rev. 2017. PMID: 28073178 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical